FOCUS: A study for people with type 2 diabetes and eye disease

Type 2 Diabetes | Diabetic Retinopathy | Diabetic Complications

The FOCUS study is being done to see if a medicine called semaglutide can reduce the risk of retinopathy progression in people with type 2 diabetes.

Inclusion Criteria:
18 years of age with type 2 diabetes
HbA1c 7-10%
History of diabetic eye disease
Exclusion Criteria:
None to list online.

University of Alberta
Edmonton, Alberta
Canada

Primary Contact

Caroline Lyster

[email protected]
780-248-1770

Primary Contact

Ruth Fazio

[email protected]
780-492-1098

Back to Search